| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 14,098 | 14,182 | 18.05. | |
| 14,076 | 14,254 | 18.05. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 15,210 | 300 | |||
| 15,100 | 408 | |||
| 15,000 | 654 | |||
| 14,494 | 3 | |||
| 14,390 | 3 | |||
| 14,388 | 420 | |||
| 14,286 | 3 | |||
| 14,176 | 420 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/via.htm [/URL] | ||||
| 420 | 14,114 | |||
| 3 | 14,026 | |||
| 423 | 13,922 | |||
| 3 | 13,818 | |||
| 444 | 7,000 | |||
| 1.083 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.376 | 0,931 | 2.211 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 14:07:07 | 14,054 | 18 |
| 09:04:50 | 14,000 | 58 |
| 09:04:50 | 14,004 | 2 |
| 09:04:50 | 14,004 | 12 |
| Tagesumsatz Xetra | -0,146 -1,02 % | 843 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Here's Why Viatris (VTRS) is a Strong Momentum Stock | 6 | Zacks | ||
| VIATRIS Aktie jetzt für 0€ handeln | |||||
| Mo | Viatris's NDA For MR-107A-02 Secures FDA Acceptance | 263 | AFX News | WASHINGTON (dpa-AFX) - Monday, Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for MR-107A-02 for the treatment of moderate-to-severe... ► Artikel lesen | |
| Mo | FDA accepts Viatris application for fast-acting meloxicam | 5 | Investing.com | ||
| Mo | Viatris Inc.: U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain | 466 | PR Newswire | FDA PDUFA Goal Date Set for Dec. 27, 2026
PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that... ► Artikel lesen | |
| Mi | Viatris übertrifft Gewinnprognose für Q1 2026 - Aktie legt deutlich zu | 30 | Investing.com Deutsch |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mo | Provectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End | GlobeNewswire (Europe) | Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE... ► Artikel lesen | |
| Mo | MPH Health Care schlägt Dividende von 5,00 Euro je Aktie vor | 4investors | Der Aufsichtsrat der MPH Health Care AG hat den Jahresabschluss und den Konzernabschluss für das Geschäftsjahr 2025 gebilligt und damit festgestellt. Vorstand und Aufsichtsrat schlagen der Hauptversammlung... ► Artikel lesen | |
| Mo | Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development | PR Newswire | Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra.Sofdra... ► Artikel lesen | |
| Mo | Photocure: AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study | PR Newswire | OSLO, Norway, May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological... ► Artikel lesen | |
| Mo | Morning Market Movers: Sunshine Biopharma, GeoVax Labs, Huachen AI Parking Management Technology, LiveRamp See Big Swings | AFX News | BEIJING (dpa-AFX) - At 8:15 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |